54,507 results match your criteria Hormonal Therapy


The long non-coding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.

Mol Oncol 2019 Feb 18. Epub 2019 Feb 18.

British Columbia Cancer Research Centre, Vancouver, BC, Canada.

Prostate Cancer (PCa) is driven by the androgen receptor (AR)-signaling axis. Hormonal therapy often mitigates PCa progression, but a notable number of cases progress to castration-resistant PCa (CRPC). CRPC retains AR-activity and is incurable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12471DOI Listing
February 2019

Large desmoid tumors in familial adenomatous polyposis: a successful outcome.

Autops Case Rep 2018 Oct-Dec;8(4):e2018045. Epub 2018 Sep 26.

Centro Hospitalar de São João, Department of Surgery. Porto, Portugal.

Desmoid tumors develop from connective tissue, fasciae, and aponeuroses, and may occur in the context of familial adenomatous polyposis or may arise sporadically; also, they may be extra-abdominal, intra-abdominal, or located in the abdominal wall. These benign tumors have a great aggressiveness with a high rate of local recurrence. Familial adenomatous polyposis is an inherited condition with autosomal dominant transmission, and is characterized by the development of multiple colonic and rectal adenomatous polyps, as well as desmoid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4322/acr.2018.045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360820PMC
September 2018

Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.

Asian J Urol 2019 Jan 28;6(1):65-81. Epub 2018 Nov 28.

Uro-Oncology Research, Department of Medicine and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

This article describes cell signaling network of metastatic prostate cancer (PCa) to bone and visceral organs in the context of tumor microenvironment and for the development of novel therapeutics. The article focuses on our recent progress in the understanding of: 1) The plasticity and dynamics of tumor-stroma interaction; 2) The significance of epigenetic reprogramming in conferring cancer growth, invasion and metastasis; 3) New insights on altered junctional communication affecting PCa bone and brain metastases; 4) Novel strategies to overcome therapeutic resistance to hormonal antagonists and chemotherapy; 5) Genetic-based therapy to co-target tumor and bone stroma; 6) PCa-bone-immune cell interaction and TBX2-WNTprotein signaling in bone metastasis; 7) The roles of monoamine oxidase and reactive oxygen species in PCa growth and bone metastasis; and 8) Characterization of imprinting cluster of microRNA, in tumor-stroma interaction. This article provides new approaches and insights of PCa metastases with emphasis on basic science and potential for clinical translation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajur.2018.11.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363607PMC
January 2019

BMS consensus statement: The risks and benefits of HRT before and after a breast cancer diagnosis.

Authors:
Jo Marsden

Post Reprod Health 2019 Feb 16:2053369119825716. Epub 2019 Feb 16.

King's College Hospital NHS Foundation Trust, London, UK.

In women at population risk of breast cancer (i.e. most), short-term exposure to hormone replacement therapy (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2053369119825716DOI Listing
February 2019

Epilepsy, depression, and growth hormone.

Epilepsy Behav 2019 Feb 14. Epub 2019 Feb 14.

Clinical and Translational Science Center, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, United States of America.

Depression affects a large proportion of patients with epilepsy, and is likely due in part to biological mechanism. Hormonal dysregulation due to the disruptive effects of seizures and interictal epileptiform discharges on the hypothalamic-pituitary-adrenal axis likely contributes to high rates of depression in epilepsy. This paper reviews the largely unexplored role of neuroendocrine factors in epilepsy-related depression, focusing on Growth Hormone (GH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2019.01.022DOI Listing
February 2019

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Eur Urol 2019 Mar 26;75(3):368-373. Epub 2018 Oct 26.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.09.049DOI Listing

[Clinical Assessment of Fourteen Cases of Thoracic Endometriosis].

Kyobu Geka 2019 Feb;72(2):87-91

Division of Thoracic Surgery,Tohoku Medical and Pharmaceutical University, Sendai, Japan.

We retrospectively assessed the clinical and pathological features of 14 patients with thoracic endometriosis who were treated at our hospital from 2007 to 2017. Thirteen patients presented pneumothorax and 1 patient presented bloody sputum. All were treated surgically. Read More

View Article

Download full-text PDF

Source
February 2019

Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.

Cancer Treat Res Commun 2019 Feb 10;19:100119. Epub 2019 Feb 10.

Florida Physician Specialists, Jacksonville, FL, USA.

Background: Prior randomized studies have shown a survival benefit using combined androgen deprivation therapy (ADT) and radiation therapy for intermediate-risk prostate cancer. However, these studies either used low doses of radiation (66.6 Gy to isocenter) or imaged guidance was not available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100119DOI Listing
February 2019

Biological Evolution of Castration-resistant Prostate Cancer.

Eur Urol Focus 2019 Feb 13. Epub 2019 Feb 13.

Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

Context: Recent studies focused on the molecular characterization of metastatic prostate cancer have identified genomic subsets and emerging resistance patterns. Detection of these alterations in patients has potential implications for therapy selection and prognostication.

Objective: The primary objective is to review the current landscape of clinical and molecular biomarkers in advanced prostate cancer and understand how they may reflect underlying tumor biology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.01.016DOI Listing
February 2019

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.

Eur J Cancer 2019 Feb 13;110:62-70. Epub 2019 Feb 13.

Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, the Netherlands. Electronic address:

Aim: Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)-positive in 67-96% of cases. In patients with locally recurrent and metastatic (R/M) AR-positive SDC, androgen deprivation therapy (ADT) has an overall response rate of 18-64.7%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.12.035DOI Listing
February 2019

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.

Lancet Oncol 2019 Feb 12. Epub 2019 Feb 12.

University College London Cancer Institute, London, UK.

Background: In the PROSPER trial, enzalutamide significantly improved metastasis-free survival in patients with non-metastatic, castration-resistant prostate cancer. Here, we report the results of patient-reported outcomes of this study.

Methods: In the randomised, double-blind, placebo-controlled, phase 3 PROSPER trial, done at 254 study sites worldwide, patients aged 18 years or older with non-metastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of up to 10 months were randomly assigned (2:1) via an interactive voice web recognition system to receive oral enzalutamide (160 mg per day) or placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30898-2DOI Listing
February 2019

Genitourinary syndrome of menopause - is the problem solved? State of the art 2018.

Prz Menopauzalny 2018 Dec 31;17(4):168-174. Epub 2018 Dec 31.

1 Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education, Warsaw, Poland.

Vulvovaginal atrophy accompanied by lower urinary tract dysfunction related to low levels of estrogen and androgens is labeled as genitourinary syndrome of menopause (GSM). Although this condition affects most postmenopausal women worldwide, it seems to be underdiagnosed and undertreated. Women should be properly advised to choose an adequate treatment modality to improve their quality of life, sexual relationships and social activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pm.2018.81741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372854PMC
December 2018

Diagnostic value of histopathological examination results obtained during screening of patients with diagnosed atypical hyperplasia.

Prz Menopauzalny 2018 Dec 31;17(4):144-148. Epub 2018 Dec 31.

Department of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.

Vulvovaginal atrophy accompanied by lower urinary tract dysfunction related to low levels of estrogen and androgens is labeled as genitourinary syndrome of menopause (GSM). Although this condition affects most postmenopausal women worldwide, it seems to be underdiagnosed and undertreated. Women should be properly advised to choose an adequate treatment modality to improve their quality of life, sexual relationships and social activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pm.2018.81734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372849PMC
December 2018

PAX8: A Highly Sensitive Marker for the Glands in Extragenital Endometriosis.

Reprod Sci 2019 Feb 14:1933719119828095. Epub 2019 Feb 14.

1 Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan.

In cases of extragenital endometriosis or microscopic endometriosis lesions, pathological diagnosis can be challenging because endometriotic stroma and glands represent only a minor component of fibrotic endometriotic lesions. For better accuracy of diagnosis, the development of a sensitive and specific epithelial marker is beneficial. Previous studies showed that PAX8 is a highly sensitive and specific marker for primary and metastatic Mullerian epithelial tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1933719119828095DOI Listing
February 2019

A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.

Expert Opin Biol Ther 2019 Feb 14. Epub 2019 Feb 14.

a Academic Unit of Obstetrics and Gynecology , Ospedale Policlinico San Martino , Largo R. Benzi 10, 16132 Genoa , Italy.

Introduction: Endometriosis is a chronic benign estrogen dependent disease characterized by the presence of endometriotic glands and stroma outside the uterine cavity. Although combined hormonal contraceptives and progestins, currently available first-line treatments for endometriosis, are efficacious and well tolerated for treating disease-related pain, some women experience partial or no improvement of pain or its recurrence is frequent after discontinuation of the therapies. For these reasons, new drugs are under investigation for the treatment of endometriosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1581761DOI Listing
February 2019

Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies.

Mod Pathol 2019 Feb 13. Epub 2019 Feb 13.

Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto Faculty of Medicine, E432-2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.

Ductal carcinoma in situ (DCIS) is a neoplastic proliferation of mammary ductal epithelial cells confined to the ductal-lobular system, and a non-obligate precursor of invasive disease. While there has been a significant increase in the diagnosis of DCIS in recent years due to uptake of mammography screening, there has been little change in the rate of invasive recurrence, indicating that a large proportion of patients diagnosed with DCIS will never develop invasive disease. The main issue for clinicians is how to reliably predict the prognosis of DCIS in order to individualize patient treatment, especially as treatment ranges from surveillance only, breast-conserving surgery only, to breast-conserving surgery plus radiotherapy and/or hormonal therapy, and mastectomy with or without radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0204-1DOI Listing
February 2019

Endometrial Regeneration in Asherman's Syndrome: Clinical and Translational evidence of Stem Cell Therapies.

Curr Stem Cell Res Ther 2019 Feb 12. Epub 2019 Feb 12.

Department of Gynaecology and Obstetrics, Geneva University Hospital, 30, bvd de la Cluse, 1205, Genève. Switzerland.

Asherman's Syndrome or Intrauterine adhesions is an acquired uterine condition where fibrous scarring forms within the uterine cavity, resulting in reduced menstrual flow, pelvic pain and infertility. Until recently, the molecular mechanisms leading to the formation of fibrosis were poorly understood, and the treatment of Asherman's syndrome has largely focused on hysteroscopic resection of adhesions, hormonal therapy, and physical barriers. Numerous studies have begun exploring the molecular mechanisms behind the fibrotic process underlying Asherman's Syndrome as well as the role of stem cells in the regeneration of the endometrium as a treatment modality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574888X14666190213100528DOI Listing
February 2019

Primary Malignant Thyroid Teratoma: An Institutional Experience.

Thyroid 2019 Feb;29(2):229-236

1 Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Primary malignant thyroid teratomas are very rare tumors (fewer than 35 previously reported cases in the literature) typically affecting young adult women. While prognosis is poor, there have been some reports of successful treatment regimens. Four cases treated successfully are reported, and a review of the existing literature is provided. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2018.0206DOI Listing
February 2019

The Turner syndrome research registry: Creating equipoise between investigators and participants.

Am J Med Genet C Semin Med Genet 2019 Feb 13. Epub 2019 Feb 13.

Division of Pediatric Cardiology, Department of Pediatrics, Oregon Health & Science University, Oregon, Portland.

To address knowledge gaps about Turner syndrome (TS) associated disease mechanisms, the Turner Syndrome Society of the United States created the Turner Syndrome Research Registry (TSRR), a patient-powered registry for girls and women with TS. More than 600 participants, parents or guardians completed a 33-item foundational survey that included questions about demographics, medical conditions, psychological conditions, sexuality, hormonal therapy, patient and provider knowledge about TS, and patient satisfaction. The TSRR platform is engineered to allow individuals living with rare conditions and investigators to work side-by-side. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajmg.c.31689DOI Listing
February 2019

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Head Neck 2019 Feb 13. Epub 2019 Feb 13.

Foundation Medicine, Inc., Cambridge, Massachusetts.

Introduction: Anaplastic thyroid cancer (ATC) is a highly aggressive thyroid cancer. Those ATC with genomic alterations (GAs) in TSC2, ALK, and BRAF may respond to targeted therapies.

Methods: Comprehensive genomic profiling on 90 ATC specimens identified base substitutions, short insertions and deletions, amplifications, copy number alterations, and genomic rearrangements in up to 315 cancer-related genes and 28 genes commonly rearranged in cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25634DOI Listing
February 2019

Regulation of autophagy as a therapy for immunosenescence-driven cancer and neurodegenerative diseases: The role of exercise.

J Cell Physiol 2019 Feb 12. Epub 2019 Feb 12.

Department of Cell and Developmental Biology, University of São Paulo, São Paulo, São Paulo, Brazil.

Aging is one of the risk factors for the development of low-grade inflammation morbidities, such as several types of cancer and neurodegenerative diseases, due to changes in the metabolism, hormonal secretion, and immunosenescence. The senescence of the immune system leads to improper control of infections and tissue damage increasing age-related diseases. One of the mechanisms that maintain cellular homeostasis is autophagy, a cell-survival mechanism, and it has been proposed as one of the most powerful antiaging therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28318DOI Listing
February 2019

Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).

Ginekol Pol 2019 ;90(1):7-10

Department of Obstetrics and Gynecology, Central Clinical Hospital of Interior, Warsaw, Poland.

Objectives: To evaluate the effects of a combined Myo-inositol (MI) and D-chiro-inositol (DCI) therapy on the hormonal and metabolic parameters of women with PCOS. Prospective clinical study. Clinical Study registration number - EUPAS25705 Material and methods: Seventy women diagnosed with PCOS according to the Rotterdam criteria were enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/GP.2019.0002DOI Listing
January 2019
5 Reads

Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol.

BMJ Open 2019 Feb 11;9(2):e023591. Epub 2019 Feb 11.

Department of Radiotherapy, Grenoble Alpes University Hospital, Grenoble, France.

Introduction: Occurrence of multiple brain metastases is a critical evolution of many cancers with significant neurological and overall survival consequences, despite new targeted therapy and standard whole brain radiotherapy (WBRT). A gadolinium-based nanoparticle, AGuIX, has recently demonstrated its effectiveness as theranostic and radiosensitiser agent in preclinical studies. The favourable toxicity profile in animals and its administration as a simple intravenous injection has motivated its use in patients with this first in human study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-023591DOI Listing
February 2019

Chlamydia trachomatis in women with pelvic inflammatory disease (PID): report from a tertiary center in eastern Nepal.

Trop Doct 2019 Feb 12:49475519826195. Epub 2019 Feb 12.

6 Additional Professor, Department of Microbiology, BP Koirala Institute of Health Sciences, Dharan, Nepal.

Chlamydia trachomatis is an important agent of pelvic inflammatory disease (PID) globally. Laboratory diagnosis, which is vital for early and appropriate treatment, remains a challenge in resource-limited settings. Our study was undertaken to detect C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0049475519826195DOI Listing
February 2019

Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.

Rheumatology (Oxford) 2019 Feb 8. Epub 2019 Feb 8.

Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.

Objectives: To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.

Methods: This observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez014DOI Listing
February 2019
2 Reads

Diffuse massive adenomyosis and infertility. Is it possible to treat this condition?

Horm Mol Biol Clin Investig 2019 Feb 6. Epub 2019 Feb 6.

Department of Perinatology, Obstetrics and Gynecology, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia.

Background Severe forms of adenomyosis are a serious gynecological problem. In most cases, conservative treatment of this pathology is unsuccessful. Adenomyomectomy by Osada's approach seems to be the most promising solution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/hmbci-2018-0026DOI Listing
February 2019
1 Read

Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

CNS Drugs 2019 Feb 11. Epub 2019 Feb 11.

Epilepsy Unit, Hôpital Gui de Chauliac, 80 Avenue Fliche, 34295, Montpellier Cedex 05, France.

Juvenile myoclonic epilepsy (JME) is both a frequent and a very characteristic epileptic syndrome with female preponderance. Treatment of JME in women of childbearing potential must consider multiple factors such as desire for pregnancy, use of contraception, seizure control and previously used antiepileptic drugs (AEDs). Approximately 85% of cases are well controlled with valproate, which remains the reference AED in JME but is nowadays considered unsafe for the expecting mother and her fetus. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40263-018-00602-2
Publisher Site
http://dx.doi.org/10.1007/s40263-018-00602-2DOI Listing
February 2019
2 Reads

Dermatologic care for lesbian, gay, bisexual, and transgender persons: Epidemiology, screening, and disease prevention.

J Am Acad Dermatol 2019 Mar;80(3):591-602

Department of Dermatology, Kaiser Permanente, San Francisco, California.

Lesbian, gay, bisexual, and transgender (LGBT) persons face important health issues relevant to dermatologists. Men who have sex with men (MSM) are at higher risk of certain infectious diseases, including HIV, syphilis and other sexually transmitted diseases (STDs), methicillin-resistant Staphylococcus aureus infections, and invasive meningococcal disease, and might be at higher risk of non-infectious conditions, including skin cancer. Recommendations for preventive health care, including screening for HIV and other STDs, sexual health-related vaccinations, and HIV pre-exposure prophylaxis, differ for MSM compared with non-MSM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.02.045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375301PMC
March 2019
1 Read

Combined hormonal contraceptives for heavy menstrual bleeding.

Cochrane Database Syst Rev 2019 Feb 11;2:CD000154. Epub 2019 Feb 11.

Department of Obstetrics and Gynaecology, University of Auckland, Private Bag 92019, Auckland, New Zealand, 1142.

Background: Menorrhagia or heavy menstrual bleeding (HMB) is an excessive blood loss that impairs a woman's quality of life, either physical, emotional, social or material. It is benign and not associated with pregnancy or any other gynaecological or systemic disease. Medical treatments used to reduce excessive menstrual blood loss (MBL) include prostaglandin synthetase inhibitors, antifibrinolytics, oral contraceptive pills, and other hormones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD000154.pub3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369862PMC
February 2019
3 Reads

Acromegaly associated with GIST, non-small cell lung cancer, clear cell renal cancer, myeloma multiplex, medulla oblongata tumor, adrenal adenoma and follicular thyroid nodules.

Endokrynol Pol 2019 Feb 11. Epub 2019 Feb 11.

Dept. of Endocrinology, Diabetes and Isotope Therapy, Medical University Wroclaw, Pasteura 4, 50-367 Wrocłąw, Poland.

Background: Acromegaly is associated with increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion which may support tumor development and growth.

Case Presentation: A 68-year old woman was diagnosed with acromegaly due to typical clinical and hormonal characteristics. While a contrast-enhanced MRI at diagnosis did not reveal a pituitary adenoma, a 5 mm lesion was identified on repeat scanning 13 months later. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/EP.a2019.0005DOI Listing
February 2019
5 Reads

The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.

Drugs 2019 Feb 11. Epub 2019 Feb 11.

Department of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131, Naples, Italy.

Prostate cancer (PC) is a major health issue in developed countries, with, on the one hand, men suffering from sequelae related to unnecessary treatment of non-lethal PC, and, on the other hand, still dying because of advanced PC that progresses to castration-resistant disease. Systemic treatment is the mainstay of therapy of castration-resistant PC (CRPC). To date, a multitude of systemic agents have been tested and many of these have failed to provide a clinically meaningful benefit in CRPC, while others have been approved by the US Food and Drug Administration and/or the European Medicines Agency, including antiandrogen hormonal drugs (abiraterone, enzalutamide, apalutamide), chemotherapy (docetaxel and cabazitaxel), immunotherapy (Sipuleucel-T), and radiopharmaceutical (Radium-223) agents. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40265-019-1060-5
Publisher Site
http://dx.doi.org/10.1007/s40265-019-1060-5DOI Listing
February 2019
1 Read

Bilateral adrenal myelolipomas presenting as acute adrenal insufficiency in an adult with congenital adrenal hyperplasia.

BMJ Case Rep 2019 Feb 9;12(2). Epub 2019 Feb 9.

Department of Internal Medicine, division of Endocrinology, Texas Tech University Health Sciences Centre School of Medicine, Lubbock, Texas, USA.

Adrenal myelolipomas are relatively rare tumours composed of adipocytes and myeloid cells that arise in response to chronic adrenocorticotropic hormone stimulation. We present the case of bilateral adrenal myelolipomas in a 39-year-old man with untreated congenital adrenal hyperplasia (CAH) presenting with acute adrenal insufficiency and severe virilisation. Phenotypically, he is a man of short stature and has hyperpigmentation of the skin, gingiva and nail beds. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226826DOI Listing
February 2019
2 Reads

Estradiol and progesterone regulate proliferation and apoptosis in colon cancer.

Endocr Connect 2019 Feb 1. Epub 2019 Feb 1.

R Carón, IMBECU, CONICET, Mendoza, 5500, Argentina.

Epidemiological studies describe estrogens as protectors in the development of colon cancer in postmenopausal women treated with hormone replacement therapy. However, the role of progesterone in colon cancer has been minimally studied and the results are controversial. For the above, the objective of this work was to determine the hormonal regulation exerted by natural ovarian steroids on proliferation and apoptosis in an experimental model of colon cancer in ovariectomized rats treated with 17 beta-estradiol and progesterone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-18-0374DOI Listing
February 2019
1 Read

Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types.

Sci Rep 2019 Feb 7;9(1):1603. Epub 2019 Feb 7.

Philips Research, High Tech Campus 11, 5656 AE, Eindhoven, The Netherlands.

Signal transduction pathways are important in physiology and pathophysiology. Targeted drugs aim at modifying pathogenic pathway activity, e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38179-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367506PMC
February 2019
2 Reads

Unrecognized Pseudohypoparathyroidism Type 1A as a Cause of Hypocalcemia and Seizures in a 64-Year-Old Woman.

Case Rep Endocrinol 2019 9;2019:8456239. Epub 2019 Jan 9.

Department of Health Sciences, University of Genoa; Medical Genetics Unit, Galliera Hospital, Genoa, Italy.

Pseudohypoparathyroidism type 1A (PHP1A) is usually diagnosed in childhood or early adulthood. We describe the case of a 64-year-old woman admitted to the Neurological Unit for recurrent episodes of loss of consciousness and seizures. Glycemia and ECG were normal, while hypocalcemia was noted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8456239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343178PMC
January 2019
1 Read

Adrenocorticotropic Hormone-Dependent Cushing Syndrome Caused by an Olfactory Neuroblastoma.

Clin Med Insights Endocrinol Diabetes 2019 31;12:1179551419825832. Epub 2019 Jan 31.

Department of Endocrinology, Hospital Clinico San Carlos, Madrid, Spain.

Olfactory neuroblastoma (ONB) is an unusual malignant neoplasm originating from the olfactory neuroepithelium. Secretion of adrenocorticotropic hormone (ACTH) from this tumor has been exceptionally reported. We describe a young man with resistant hypertension and a cushingoid phenotype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179551419825832DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357293PMC
January 2019
1 Read

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.

J Immunother Cancer 2019 Feb 6;7(1):31. Epub 2019 Feb 6.

Departments of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Immune checkpoint inhibitor (ICI)-induced pancreatic injury (ICIPI) is not well documented in the literature. We aimed to describe the clinical characteristics and outcomes of patients who developed ICIPI.

Methods: We reviewed the medical records of consecutive patients who had a confirmed diagnosis of ICIPI (Common Terminology Criteria for Adverse Events grade ≥ 3 lipase elevation with or without clinical symptoms) from April 2011 through April 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0502-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364483PMC
February 2019

Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: a hospital-based study.

BMC Womens Health 2019 Feb 6;19(1):28. Epub 2019 Feb 6.

PILAR Research and Education, 20 Station Road, Cambridge, CB1 2JD, UK.

Background: Breast cancer diagnosed at a young age is often associated with aggressive biology, advanced stage, and unfavorable prognosis. The median age of breast cancer diagnosis in Indonesia is younger (48 vs. 68 years-old in Europe) with a relatively higher proportion of patients younger than 40 years old. Read More

View Article

Download full-text PDF

Source
https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s
Publisher Site
http://dx.doi.org/10.1186/s12905-019-0724-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364389PMC
February 2019
1 Read
1.657 Impact Factor

[Does menopause hormone therapy reduce the risk of chronic diseases?]

Rev Med Chil 2018 Dec;146(10):1170-1174

Departamento de Endocrinología, Programa de Endocrinología Ginecológica, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

The hormonal deficit of post menopause is not only linked to the classic hot flashes, but also to a higher risk of chronic diseases. Menopausal hormone therapy (MHT) adequately treats climacteric symptoms and can prevent some chronic diseases such as osteoporosis. The Women's Health Initiative (WHI) study, which indicated risks of MHT in elderly postmenopausal women, caused a massive withdrawal of this therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0034-98872018001001170DOI Listing
December 2018
2 Reads

[Vaginal laser therapy for urinary incontinence and genitourinary syndrome of menopause : A review].

Authors:
C Ratz

Urologe A 2019 Feb 5. Epub 2019 Feb 5.

Urologie Groß-Gerau, Am Sandböhl 2, 64521, Groß-Gerau, Deutschland.

Background: Use of vaginal laser therapy in the treatment of grade I stress urinary incontinence and genitourinary syndrome of menopause is gaining in importance across the globe.

Materials And Methods: On the basis of the research that is currently available, an analysis is carried out regarding whether laser therapy is already suitable for use in the field of urology.

Results: The research available is still limited: randomized controlled studies in particular are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00120-019-0861-1DOI Listing
February 2019
1 Read

[Clinical and functional characteristics of giant pituitary adenomas in the population of patients in the Moscow region].

Zh Vopr Neirokhir Im N N Burdenko 2018 ;82(6):76-81

Moscow Regional Researh and Clinical Institute, Moscow, Russia.

Benign pituitary tumors are the most common sellar neoplasms. Lesions larger than 39 mm in the maximum dimension are called giant. They are rare, and, therefore, there are few data on the clinical and morphological features of giant pituitary tumors with different hormonal activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/neiro20188206176DOI Listing
January 2018
1 Read

ENDOCRINE OUTCOMES OF TRANS-SPHENOIDAL SURGERY FOR PITUITARY APOPLEXY VERSUS ELECTIVE SURGERY FOR PITUITARY ADENOMA.

Endocr Pract 2019 Jan 18. Epub 2019 Jan 18.

Department of Neurological Surgery.

Objective: To determine the rate of hormone replacement therapy (HRT) after transsphenoidal surgery (TSS) for pituitary apoplexy (PA) vs. elective resection of a null cell (NC) macroadenoma.

Methods: A retrospective cohort study was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4158/EP-2018-0488DOI Listing
January 2019
1 Read

Clinical perspectives in congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase type 2 deficiency.

Endocrine 2019 Feb 4. Epub 2019 Feb 4.

Division of Medicine, Royal Darwin Hospital, Darwin, NT, Australia.

Purpose: 3β-hydroxysteroid dehydrogenase type 2 deficiency (3βHSD2D) is a very rare variant of congenital adrenal hyperplasia (CAH) causing less than 0.5% of all CAH. The aim was to review the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-018-01835-3DOI Listing
February 2019
2 Reads

Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy.

Eur J Oncol Nurs 2019 Feb 12;38:8-12. Epub 2018 Nov 12.

Division of Medical Oncology 1, IRCCS "Regina Elena" National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. Electronic address:

Purpose: To explore adherence to oral hormone treatment in patients with metastatic prostate cancer (mCRPC) and to identify the factors that influence it.

Methods: A qualitative exploratory study was conducted at the National Cancer Institute of Rome. Patients aged >18 years with castration-resistant prostate cancer (mCRPC) and who were using oral hormone drugs were recruited. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14623889183013
Publisher Site
http://dx.doi.org/10.1016/j.ejon.2018.11.004DOI Listing
February 2019
4 Reads

Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer.

Endocrinol Metab Clin North Am 2019 03 11;48(1):253-268. Epub 2018 Dec 11.

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1461, Houston, TX 77030, USA. Electronic address:

Systemic therapy options have emerged for treatment of progressive, radioiodine-refractory differentiated thyroid carcinoma. Approved therapies that target tumor angiogenesis, lenvatinib and sorafenib, improve progression-free survival and, in an older subset, lenvatinib can prolong overall survival. Treatments based on targeting specific somatic genetic alterations are also available, which potentially also may prolong progression-free survival but are not yet approved for use by the Food and Drug Administration for this specific disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ecl.2018.10.009DOI Listing
March 2019
2 Reads

Prohibitin: A hypothetical target for sex-based new therapeutics for metabolic and immune diseases.

Exp Biol Med (Maywood) 2019 Feb 4:1535370219828362. Epub 2019 Feb 4.

1 Department of Internal Medicine, University of Manitoba, Manitoba R3A1R9, Canada.

Impact Statement: Traditional sex-related biases in research are now obsolete, and it is important to identify the sex of humans, animals, and even cells in research protocols, due to the role of sex as a fundamental facet of biology, predisposition to disease, and response to therapy. Genetic sex, epigenetics and hormonal regulations, generate sex-dimorphisms. Recent investigations acknowledge sex differences in metabolic and immune health as well as chronic diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1535370219828362DOI Listing
February 2019
3 Reads

Synthesis and Reactivity of 6,8-Dibromo-2-ethyl-4H-benzo[d][1,3]oxazin-4-one Towards Nucleophiles and Electrophiles and Their Anticancer Activity.

Anticancer Agents Med Chem 2019 Feb 1. Epub 2019 Feb 1.

University of Ain Shams, Faculty of Science, Department of Zoology, Abbassia 11566, Cairo. Egypt.

Background And Methods: The genetic heterogeneity of tumor cells and the development of therapy-resistant cancer cells in addition to the high cost necessitate the continuous development of novel targeted therapies. In this regard, 14 novel benzoxazinone derivatives were synthesized and examined for anticancer activity against two human epithelial cancer cell lines; breast MCF-7 and liver HepG2 cells. 6,8-Dibromo-2-ethyl-4H-benzo[d][1,3]oxazin-4-one was subjected to react with nitrogen nucleophiles to afford quinazolinone derivatives and other related moieties (3-12). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871520619666190201145221DOI Listing
February 2019
1 Read

Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review.

Acta Obstet Gynecol Scand 2019 Feb 3. Epub 2019 Feb 3.

Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.

Introduction: Atypical polypoid adenomyoma (APA) is an uncommon uterine lesion, which can coexist with endometrial atypical hyperplasia and/or cancer. APA affects premenopausal women in most cases, but it shows high recurrence rate if conservatively treated. To date, the management of patients is based on low quality evidence and not standardized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13553DOI Listing
February 2019
1 Read
1.985 Impact Factor

Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.

Lancet Oncol 2019 Jan 31. Epub 2019 Jan 31.

Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK; Leeds Institute for Data Analytics, University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Background: Little is known about the health-related quality of life (HRQOL) of men living with advanced prostate cancer. We report population-wide functional outcomes and HRQOL in men with all stages of prostate cancer and identify implications for health-care delivery.

Methods: For this population-based study, men in the UK living 18-42 months after diagnosis of prostate cancer were identified through cancer registration data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30780-0DOI Listing
January 2019
2 Reads